Afficher la couverture 'Changes in clinical practice related to the arrival of next-generation sequencing in the genetic diagnosis of developmental diseases. Les modifications de pratique clinique liées à l’arrivée du séquençage haut débit dans le diagnostic génétique des maladies du développement | Demougeot, L.' en grand format
/5

0 avis

Changes in clinical practice related to the arrival of next-generation sequencing in the genetic diagnosis of developmental diseases. Les modifications de pratique clinique liées à l’arrivée du séquençage haut débit dans le diagnostic génétique des maladies du développement

Archive ouverte

Demougeot, L. | Houdayer, F. | Pélissier, A. | Mohrez, F. | Thevenon, J. | Duffourd, Y. | Nambot, S. | Gautier, E. | Binquet, C. | Rossi, M. | Sanlaville, D. | Bejean, S. | Peyron, C. | Thauvin-Robinet, C. | Faivre, L.

Edité par CCSD ; Elsevier -

IF 0.372. International audience. IntroductionThe arrival of high-throughput sequencing (HTS) has led to a sweeping change in the diagnosis of developmental abnormalities (DA) with or without intellectual deficiency (ID). With the prospect of deploying these new technologies, two questions have been raised: the representations of HTS among geneticists and the costs incurred due to these analyses.MethodsGeneticists attending a clinical genetics seminar were invited to complete a questionnaire. The statistical analysis was essentially descriptive and an analysis of costs was undertaken.ResultsOf those responding to the questionnaire, 48% had already prescribed exome analysis and 25% had already had the occasion to disclose the results of such analyses. Ninety-six percent were aware that whole-exome sequencing (WES) had certain limits and 74% expressed misgivings concerning its use in medical practice. In parallel, the evaluation of costs showed that WES was less expensive than conventional procedures.DiscussionThe survey revealed that geneticists had already come to terms with HTS as early as 2015. Among the major concerns expressed were the complexity of interpreting these tests and the many ethical implications. Geneticists seemed to be aware of the advantages but also the limits of these new technologies. The cost analysis raises questions about the place of HTS and in particular WES in the diagnostic work-up: should it be used early to obtain an etiological diagnosis rather than as the last resort?ConclusionIt is essential for future generations of doctors and for the families concerned to learn about the concepts of HTS, which is set to become a major feature of new genomic medicine.

Consulter en ligne

Suggestions

Du même auteur

Secondary findings from whole-exome/genome sequencing evaluating stakeholder perspectives. A review of the literature

Archive ouverte | Delanne, J. | CCSD

IF 2.004 (2017). International audience. With the development of next generation sequencing, beyond identifying the cause of manifestations that justified prescription of the test, other information with potential ...

Toward clinical and molecular dissection of frontonasal dysplasia with facial skin polyps: From Pai syndrome to differential diagnosis through a series of 27 patients.

Archive ouverte | Lehalle, D. | CCSD

International audience. Unique or multiple congenital facial skin polyps are features of several rare syndromes, from the most well-known Pai syndrome (PS), to the less recognized oculoauriculofrontonasal syndrome (...

Integrated genome and transcriptome analyses solves about one third of the patients with rare developmental disorders and negative first-line molecular investigations

Archive ouverte | Vitobello, A. | CCSD

International audience

Chargement des enrichissements...